{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T10:42:03Z","timestamp":1775904123427,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,11,23]],"date-time":"2005-11-23T00:00:00Z","timestamp":1132704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1038\/sj.npp.1300960","type":"journal-article","created":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T05:49:53Z","timestamp":1133416193000},"page":"1274-1285","source":"Crossref","is-referenced-by-count":44,"title":["Multiple Dose Pharmacokinetics of Paroxetine in Children and Adolescents with Major Depressive Disorder or Obsessive\u2013Compulsive Disorder"],"prefix":"10.1038","volume":"31","author":[{"given":"Robert L","family":"Findling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Nucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni A","family":"Piergies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Gomeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward I","family":"Bartolic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regan","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Steven","family":"Leeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gaedigk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore M","family":"Danoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,11,23]]},"reference":[{"key":"BF1300960_CR1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/00004583-199804000-00016","volume":"37","author":"J Alderman","year":"1998","unstructured":"Alderman J, Wolkow R, Chung M, Johnston HF (1998). Sertraline treatment of children and adolescents with obsessive\u2013compulsive disorder or depression: pharmacokinetics, tolerability and efficacy. J Am Acad Child Adolesc Psychiatry 37: 386\u2013394.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"BF1300960_CR2","unstructured":"American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (DSM-IV). American Psychiatric Association: Washington, DC, 886pp."},{"key":"BF1300960_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1046\/j.1365-2125.1998.00764.x","volume":"46","author":"DG Bailey","year":"1998","unstructured":"Bailey DG, Malcolm J, Arnold O, Spence JD (1998). Grapefruit juice-drug interactions. Br J Clin Pharmacol 46: 101\u2013110.","journal-title":"Br J Clin Pharmacol"},{"key":"BF1300960_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/sj.bjp.0702074","volume":"125","author":"JC Beique","year":"1998","unstructured":"Beique JC, de Montigny C, Blier P, Debonnel G (1998). Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. Br J Pharmacol 125: 526\u2013532.","journal-title":"Br J Pharmacol"},{"key":"BF1300960_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1124\/dmd.31.3.289","volume":"31","author":"KM Bertelsen","year":"2003","unstructured":"Bertelsen KM, Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ (2003). Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Disp 31: 289\u2013293.","journal-title":"Drug Metab Disp"},{"key":"BF1300960_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2125.1992.tb04082.x","volume":"33","author":"JC Bloomer","year":"1992","unstructured":"Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT (1992). The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 33: 521\u2013523.","journal-title":"Br J Clin Pharmacol"},{"key":"BF1300960_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/00004583-200301000-00007","volume":"42","author":"A Braconnier","year":"2003","unstructured":"Braconnier A, Le Coent R, Cohen D, DEROXADO Study Group (2003). Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 42: 22\u201329.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"BF1300960_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1365-2125.1992.tb04134.x","volume":"34","author":"HK Crewe","year":"1992","unstructured":"Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992). The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34: 262\u2013265.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 11","key":"BF1300960_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1289\/ehp.94102s11111","volume":"102","author":"WR Crom","year":"1994","unstructured":"Crom WR (1994). Pharmacokinetics in the child. Environ Health Perspect 102 (Suppl 11): 111\u2013117.","journal-title":"Environ Health Perspect"},{"issue":"Suppl","key":"BF1300960_CR10","first-page":"13","volume":"53","author":"CL DeVane","year":"1992","unstructured":"DeVane CL (1992). Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 53 (Suppl): 13\u201320.","journal-title":"J Clin Psychiatry"},{"key":"BF1300960_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/00004714-200010000-00021","volume":"20","author":"RS Diler","year":"2000","unstructured":"Diler RS, Tamam L, Avci A (2000). Withdrawal symptoms associated with paroxetine discontinuation in a nine-year-old boy. J Clin Psychopharmacol 20: 586\u2013587.","journal-title":"J Clin Psychopharmacol"},{"key":"BF1300960_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0011-393X(02)80063-7","volume":"63","author":"RL Findling","year":"2002","unstructured":"Findling RL, Myers C, O'Riordan MA, Branicky LA, Pettigrew A, Reed MD et al (2002). An open-label dosing study of paroxetine in depressed youths. Curr Ther Res 63: 588\u2013601.","journal-title":"Curr Ther Res"},{"key":"BF1300960_CR13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/00004583-199908000-00010","volume":"38","author":"RL Findling","year":"1999","unstructured":"Findling RL, Reed MD, Myers C, O'Riordan MA, Fiala S, Branicky L et al (1999). Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 38: 952\u2013959.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"BF1300960_CR14","unstructured":"Food and Drug Administration (2004a). FDA Statement on Recommendations of the Psychopharmacologic Drugs and Pediatric Advisory Committees. Available at: http:\/\/www.fda.gov\/bbs\/topics\/news\/2004\/NEW01116.html (accessed September 30, 2004)."},{"key":"BF1300960_CR15","unstructured":"Food and Drug Administration (2004b). FDA Launches a Multi-Pronged Strategy to Strengthen Safeguards for Children Treated With Antidepressant Medications. Available at: http:\/\/www.fda.gov\/bbs\/topics\/news\/2004\/NEW01124.html (accessed October 15, 2004)."},{"key":"BF1300960_CR16","doi-asserted-by":"crossref","unstructured":"Gaedigk A, Bhathena A, Ndjountsche L, Pearce RE, Abdel-Rahman SM, Alander SW et al (2005a). Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J print copy in press (originally published online March 15, 2005, at www.nature.com\/tpj\/ ).","DOI":"10.1038\/sj.tpj.6500321"},{"key":"BF1300960_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1067\/mcp.2002.125783","volume":"72","author":"A Gaedigk","year":"2002","unstructured":"Gaedigk A, Bradford LD, Marcucci KA, Leeder JS (2002). Unique CYP2D6 activity distribution and genotype\u2013phenotype discordance in African Americans. Clin Pharmacol Ther 72: 76\u201389.","journal-title":"Clin Pharmacol Ther"},{"key":"BF1300960_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/01213011-199912000-00002","volume":"9","author":"A Gaedigk","year":"1999","unstructured":"Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Leeder JS (1999). Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9: 669\u2013682.","journal-title":"Pharmacogenetics"},{"key":"BF1300960_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.clpt.2004.10.014","volume":"77","author":"A Gaedigk","year":"2005","unstructured":"Gaedigk A, Ndjountsche L, Bradford LD, Leeder JS (2005b). Limited association of the 2988G>A SNP with CYP2D6*41 in African Americans. Clin Pharmacol Ther 77: 228\u2013230.","journal-title":"Clin Pharmacol Ther"},{"key":"BF1300960_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0009-9236(03)00067-5","volume":"73","author":"A Gaedigk","year":"2003","unstructured":"Gaedigk A, Ndjountsche L, Gaedigk R, Bradford LD, Leeder JS (2003a). Discovery of a novel non-functional cytochrome P4502D6 allele, CYP2D6*42, in African-Americans. Clin Pharmacol Ther 73: 575\u2013576.","journal-title":"Clin Pharmacol Ther"},{"key":"BF1300960_CR21","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1373\/49.6.1008","volume":"49","author":"A Gaedigk","year":"2003","unstructured":"Gaedigk A, Ryder DL, Bradford LD, Leeder JS (2003b). CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay testing for the \u22121584G promoter polymorphism. Clin Chem 49: 1008\u20131011.","journal-title":"Clin Chem"},{"issue":"Suppl 1","key":"BF1300960_CR22","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1089\/104454603322126313","volume":"13","author":"DA Geller","year":"2003","unstructured":"Geller DA, Biederman J, Stewart SE, Mullin B, Farrell C, Wagner KD et al (2003). Impact of comorbidity on treatment response to paroxetine in pediatric obsessive\u2013compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? J Child Adolesc Psychopharmacol 13 (Suppl 1): S19\u2013S29.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"BF1300960_CR23","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1097\/01.chi.0000138356.29099.f1","volume":"43","author":"DA Geller","year":"2004","unstructured":"Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E et al (2004). Paroxetine treatment in children and adolescents with obsessive\u2013compulsive disorder: a randomized, multicenter, double-blind placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 43: 1387\u20131396.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl","key":"BF1300960_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1600-0447.1989.tb07183.x","volume":"350","author":"RE Haddock","year":"1989","unstructured":"Haddock RE, Jackson D, Woods FR (1989). Paroxetine: lack of effect on hepatic drug metabolizing enzymes. Acta Psychiatr Scand 350 (Suppl): 93\u201394.","journal-title":"Acta Psychiatr Scand"},{"key":"BF1300960_CR25","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","volume":"36","author":"J Kaufman","year":"1997","unstructured":"Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P et al (1997). Schedule for affective disorders and schizophrenia in school-age children\u2014present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36: 980\u2013988.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"BF1300960_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1600-0447.1989.tb07176.x","volume":"350","author":"CM Kaye","year":"1989","unstructured":"Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD et al (1989). A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 350: 60\u201375.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"BF1300960_CR27","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/00004583-200107000-00010","volume":"40","author":"MB Keller","year":"2001","unstructured":"Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B et al (2001). Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40: 762\u2013772.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"BF1300960_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1600-0773.1979.tb02332.x","volume":"44","author":"J Lund","year":"1979","unstructured":"Lund J, Lomholt B, Fabricius J, Christensen JA, Bechgaard E (1979). Paroxetine: pharmacokinetics, tolerance and depletion of blood 5-HT in man. Acta Pharmacol Toxicol (Copenh) 44: 289\u2013295.","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"BF1300960_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/026988118700100405","volume":"1","author":"CA Marsden","year":"1987","unstructured":"Marsden CA, Tyrer P, Casey P, Seivewright N (1987). Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. J Psychopharmacol 1: 244\u2013250.","journal-title":"J Psychopharmacol"},{"key":"BF1300960_CR30","unstructured":"Milin RP, Simeon J, Spenst WP (1999). Double-blind study of paroxetine in adolescents with unipolar depression. Poster presented at the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, Chicago, IL, October 19\u201324, NR63, pp 104\u2013105 (abstract)."},{"key":"BF1300960_CR31","first-page":"235","volume-title":"Pharmacokinetics in Drug Development: Clinical Study Design and Analysis","author":"K Muir","year":"2004","unstructured":"Muir K, Gomeni R (2004). Non-compartmental analysis. In: Bonate PL, Howard DR (eds). Pharmacokinetics in Drug Development: Clinical Study Design and Analysis. AAPS Press: Arlington, VA. pp 235\u2013266."},{"key":"BF1300960_CR32","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1176\/appi.ajp.160.10.1830","volume":"160","author":"GM Murphy Jr","year":"2003","unstructured":"Murphy Jr GM, Kremer C, Rodrigues HE, Schatzberg AF (2003). Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160: 1830\u20131835.","journal-title":"Am J Psychiatry"},{"key":"BF1300960_CR33","unstructured":"National Institute of Mental Health (1985). Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 21: 839\u2013842."},{"key":"BF1300960_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/00004714-199910000-00014","volume":"19","author":"V Ozdemir","year":"1999","unstructured":"Ozdemir V, Tyndale RF, Reed K, Herrmann N, Sellers EM, Kalow W et al (1999). Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. J Clin Psychopharmacol 19: 472\u2013475.","journal-title":"J Clin Psychopharmacol"},{"key":"BF1300960_CR35","first-page":"979","volume":"21","author":"EO Poznanski","year":"1985","unstructured":"Poznanski EO, Freeman LN, Mokros HB (1985). Children's depression rating scale revised. Psychopharmacol Bull 21: 979\u2013989.","journal-title":"Psychopharmacol Bull"},{"key":"BF1300960_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1600-0447.1989.tb07171.x","volume":"350","author":"P Raptopoulos","year":"1989","unstructured":"Raptopoulos P, McClelland GR, Jackson D (1989). The clinical pharmacology of paroxetine in healthy subjects. Acta Psychiatr Scand Suppl 350: 46\u201348.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"BF1300960_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00007691-200004000-00001","volume":"22","author":"BB Rasmussen","year":"2000","unstructured":"Rasmussen BB, Brosen K (2000). Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 22: 143\u2013154.","journal-title":"Ther Drug Monit"},{"key":"BF1300960_CR38","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/00004583-199710000-00027","volume":"36","author":"F Rey-Sanchez","year":"1997","unstructured":"Rey-Sanchez F, Gutierrez-Casares JR (1997). Paroxetine in children with major depressive disorder: an open trial. J Am Acad Child Adolesc Psychiatry 36: 1443\u20131447.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"BF1300960_CR39","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00228-004-0792-6","volume":"60","author":"K Sawamura","year":"2004","unstructured":"Sawamura K, Suzuki Y, Someya T (2004). Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 60: 553\u2013557.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF1300960_CR40","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","volume":"36","author":"L Scahill","year":"1997","unstructured":"Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK et al (1997). Children's Yale\u2013Brown obsessive compulsive scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36: 844\u2013852.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"BF1300960_CR41","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/clpt.1992.24","volume":"51","author":"SH Sindrup","year":"1992","unstructured":"Sindrup SH, Brosen K, Gram LF (1992a). Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 51: 288\u2013295.","journal-title":"Clin Pharmacol Ther"},{"key":"BF1300960_CR42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/clpt.1992.23","volume":"51","author":"SH Sindrup","year":"1992","unstructured":"Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A et al (1992b). The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51: 278\u2013287.","journal-title":"Clin Pharmacol Ther"},{"key":"BF1300960_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00179933","volume":"93","author":"DR Thomas","year":"1987","unstructured":"Thomas DR, Nelson DR, Johnson AM (1987). Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 93: 193\u2013200.","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl","key":"BF1300960_CR44","first-page":"7","volume":"53","author":"IF Tulloch","year":"1992","unstructured":"Tulloch IF, Johnson AM (1992). The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry 53 (Suppl): 7\u201312.","journal-title":"J Clin Psychiatry"},{"key":"BF1300960_CR45","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/archpsyc.61.11.1153","volume":"61","author":"KD Wagner","year":"2004","unstructured":"Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P et al (2004). A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61: 1153\u20131162.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1300960_CR46","unstructured":"Wagner KD, Birmaher B, Carlson G, Clarke G, Emslie G, Geller B et al (1998). Safety of paroxetine and imipramine in the treatment of adolescent depression. Presented at the Annual Meeting of the NIMH New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, USA, 10\u201313 June 1998."},{"key":"BF1300960_CR47","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2165\/00023210-200216060-00006","volume":"16","author":"AJ Wagstaff","year":"2002","unstructured":"Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL (2002). Spotlight on paroxetine in psychiatric disorders in adults. CNS Drugs 16: 425\u2013434.","journal-title":"CNS Drugs"},{"key":"BF1300960_CR48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1126\/science.276.5309.122","volume":"276","author":"GB West","year":"1997","unstructured":"West GB, Brown JH, Enquist BJ (1997). A general model for the origin of allometric scaling laws in biology. Science 276: 122\u2013126.","journal-title":"Science"},{"key":"BF1300960_CR49","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/00004714-200212000-00006","volume":"22","author":"TE Wilens","year":"2002","unstructured":"Wilens TE, Cohen L, Biederman J, Abrams A, Neft D, Faird N et al (2002). Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol 22: 568\u2013575.","journal-title":"J Clin Psychopharmacol"},{"key":"BF1300960_CR50","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.clpt.2004.08.020","volume":"76","author":"I Zineh","year":"2004","unstructured":"Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K et al (2004). Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76: 536\u2013544.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/1300960.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300960","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300960.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T06:50:32Z","timestamp":1684219832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1300960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,23]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["BF1300960"],"URL":"https:\/\/doi.org\/10.1038\/sj.npp.1300960","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,23]]}}}